Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Neoplasms × Radiotherapy × Clear all

Status

Sponsor Class

OTHER 60 INDUSTRY 6 NIH 4 OTHER_GOV 1

Study Type

Observational 1

Sponsor

Conditions

Rectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 3 Glioblastoma 3 Esophageal Neoplasms 3 Breast Neoplasms 3 Lung Neoplasms 2 Carcinoma, Hepatocellular 2 To Study Immunostatus of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Pulmonary Fibrosis 1 Prostatic Neoplasms 1 Ototoxicity 1 Neoplasms 1 MSS Metastatic Colorectal Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Ketosis 1 Insulin Resistance 1 Hearing Loss 1 Glioma 1 Germinoma 1 Esophageal Squamous Cell Carcinoma 1 Cognitive Dysfunction 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Acquired Immunodeficiency Syndrome 1

Interventions

Drug Therapy 4 pembrolizumab 3 Thermography 2 Surveys and Questionnaires 2 Quality of Life 2 Preoperative Exercise 2 Nivolumab 2 Moxibustion 2 Hematologic Tests 2 Cyclophosphamide 2 Chemoradiotherapy 2 sinovac COVID-19 vaccine 1 lenvatinib 1 ibrutinib 1 fludarabine 1 encorafenib 1 durvalumab 1 binimetinib 1 beta Carotene 1 avelumab 1 atezolizumab 1 Zoledronic Acid 1 Zinc 1 Vitamin E 1 Vascular Access Devices 1 Validation Studies as Topic 1 Urination 1 Ultraviolet Therapy 1 Ultrasonography 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551857 2025-04-16

CaSPiN

Turku University Hospital

Ototoxicity, Neoplasms, Hearing Loss, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡